It was reported on Tuesday that the European Commission has granted final approval to US-based companies Mylan (NASDAQ: MYL) and Pfizer Inc (NYSE: PFE) for the proposed combination of their Upjohn business.
The European Commission offered conditional approval in April 2020 that was subject to the divestiture of certain of Mylan's products in Europe.
The European Commission approved the proposed divestiture buyers and Mylan signed the contract with those customers on terms that the European Commission has accepted. Both firms have already received approval from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission related to combining this business.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval